HeiLongJiang ZBD Pharmaceutical News

Heilongjiang ZBD Pharmaceutical Secures Approval for Chemical Raw Material Drug Listing

MT NewswiresDec 17, 2024 03:44 ET

ZBD Pharma Gets China Approval for Antibacterial Injection

MT NewswiresDec 3, 2024 02:59 ET

Heilongjiang ZBD Pharmaceutical Co., Ltd.'s (SHSE:603567) Stock Price Dropped 3.8% Last Week; Private Equity Firms Would Not Be Happy

Simply Wall StNov 18, 2024 22:22 ET

While Shareholders of Heilongjiang ZBD Pharmaceutical (SHSE:603567) Are in the Red Over the Last Three Years, Underlying Earnings Have Actually Grown

Simply Wall StOct 25, 2024 00:39 ET

We Think Heilongjiang ZBD Pharmaceutical (SHSE:603567) Can Stay On Top Of Its Debt

Simply Wall StOct 3, 2024 23:52 ET

China Rejects ZBD Pharmaceutical's Application For Skin Infection Drug

MT NewswiresAug 27, 2024 01:56 ET

Improved Earnings Required Before Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHSE:603567) Shares Find Their Feet

Simply Wall StAug 20, 2024 23:34 ET

Private Equity Firms Are Heilongjiang ZBD Pharmaceutical Co., Ltd.'s (SHSE:603567) Biggest Owners and Were Hit After Market Cap Dropped CN¥517m

Simply Wall StJul 29, 2024 18:18 ET

ZBD Pharmaceutical Gets Nod to Market Bromhexine Hydrochloride Injection

MT NewswiresJul 19, 2024 02:19 ET

ZBD Pharmaceutical Gets Nod to Trial Qingjianghewei Granules

MT NewswiresJul 11, 2024 05:19 ET

Investors Three-year Losses Continue as Heilongjiang ZBD Pharmaceutical (SHSE:603567) Dips a Further 4.6% This Week, Earnings Continue to Decline

Simply Wall StJun 19, 2024 21:56 ET

ZBD Pharma Gets China Approval for Gastric Acid Inhibiting Tablets

MT NewswiresMay 27, 2024 05:47 ET

Heilongjiang ZBD Pharmaceutical Co., Ltd.'s (SHSE:603567) Stock Is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?

Simply Wall StMay 9, 2024 20:02 ET

China Grants Drug Registration Approval for ZBD Pharma's Anti-Epilepsy Injectable

MT NewswiresMay 7, 2024 05:22 ET

Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHSE:603567) Looks Inexpensive But Perhaps Not Attractive Enough

Simply Wall StApr 18, 2024 01:36 ET

Earnings Growth of 108% Over 1 Year Hasn't Been Enough to Translate Into Positive Returns for Heilongjiang ZBD Pharmaceutical (SHSE:603567) Shareholders

Simply Wall StMar 7, 2024 18:26 ET

ZBD Pharma Gets Nod for Tofacitinib Citrate Tablets

MT NewswiresFeb 20, 2024 23:36 ET

Private Equity Firms in Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHSE:603567) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 12% Last Week

Simply Wall StFeb 9, 2024 19:29 ET

Heilongjiang ZBD Pharmaceutical (SHSE:603567) Is Making Moderate Use Of Debt

Simply Wall StDec 18, 2023 01:37 ET

Heilongjiang ZBD Pharmaceutical Co., Ltd.'s (SHSE:603567) Largest Shareholders Are Private Equity Firms Who Were Rewarded as Market Cap Surged CN¥902m Last Week

Simply Wall StNov 7, 2023 02:38 ET